Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including ...

A Northwestern Medicine study published in Nature Communications has revealed how HIV can protect infected cells by altering ...

An HIV-derived nucleoside therapy now treats rare genetic diseases by restoring mitochondrial DNA and improving muscle ...

HIV hijacks SRRM2 to enlarge nuclear speckles, stabilizing CPSF6 puncta and promoting efficient viral replication.

The clinical trial success of bepirovirsen, which will be submitted to regulatory agencies for approval, could be a boon for ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best affordable healthcare stocks to buy now. Gilead Sciences, Inc.

A new meeting report was published in Volume 17, Issue 12 of Aging-US on December 23, 2025, titled "Cellular senescence meets ...

Immunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference Reaching more metastatic uveal melanoma patients ...

Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and ...

Human Immunodeficiency Virus (HIV) is a virus that attacks the body’s immune system, specifically the CD4 (T) cells, which ...